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Abstract: Aggressive chemotherapy may lead to permanent male infertility. Prepubertal males do
not generate sperm, but their testes do contain spermatogonial cells (SPGCs) that could be used for
fertility preservation. In the present study, we examined the effect of busulfan (BU) on the SPGCs
of immature mice, and the possible induction of the survivor SPGCs to develop spermatogenesis
in 3D in-vitro culture. Immature mice were injected with BU, and after 0.5–12 weeks, their testes
were weighed and evaluated histologically compared to the control mice. The spermatogonial cells
[Sal-like protein 4 (SALL4) and VASA (a member of the DEAD box protein family) in the testicular
tissue were counted/seminiferous tubule (ST). The cells from the STs were enzymatically isolated and
cultured in vitro. Our results showed a significant decrease in the testicular weight of the BU-treated
mice compared to the control. This was in parallel to a significant increase in the number of severely
damaged STs, and a decrease in the number of SALL4 and VASA/STs compared to the control.
The cultures of the isolated cells from the STs of the BU-treated mice showed a development of
colonies and meiotic and post-meiotic cells after four weeks of culture. The addition of homogenates
from adult GFP mice to those cultures induced the development of sperm-like cells after four weeks
of culture. This is the first study demonstrating the presence of biologically active spermatogonial
cells in the testicular tissue of BU-treated immature mice, and their capacity to develop sperm-like
cells in vitro.
Keywords: chemotherapy; male infertility; spermatogenesis; testis; three-dimensional culture;
spermatogonial cells
Int. J. Mol. Sci. 2018, 19, 3804; doi:10.3390/ijms19123804 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 3804 2 of 16
1. Introduction
Spermatogenesis is the process of proliferation and differentiation of spermatogonial stem cells
(SSCs) to generate sperm. SSCs are located at the periphery of the seminiferous tubules close to the
basement membrane [1–8]. The relative number of these cells compared to the testicular germ cells is
very low—only around 0.03% [9,10]. While the rate of division of SSCs is very low, the division of their
progeny is very high [3,6,8]. Therefore, the progeny is more affected by chemotherapy/ radiotherapy
treatments, and anti-cancer or other disease treatments may lead to male infertility. Thanks to efficient
treatment protocols, around 80% of chemotherapy/radiotherapy-treated patients now survive the
disease [11–15].
Busulfan (BU) is an alkylating agent (leading to the formation of DNA–DNA and DNA–protein
cross-links and single strand breaks) that is used in chemotherapy for the treatment of various cancers,
and before bone marrow transplantation [16–18]. However, it causes gonadal dysfunction, kills mainly
spermatogonial cells, and even may lead to azoospermia [19]. In addition, the functionality of testicular
somatic cells may be affected by chemotherapy/radiotherapy treatments [20–24]; this may affect the
SSCs’ microenvironment and niches, and, thus, is involved in male infertility. Indeed, BU treatment is
used to deplete the spermatogonial cells in adult mice, which will be used in germ cell transplantation
technology [19,25–27]. It was shown that the restoration of spermatogenesis in BU-treated adult
mice was dose-dependent when the aggressive effect was in a dose of 45 mg/kg [24]. In addition,
it was shown that the GDNF (glial cell line derived nerve growth factor) levels increased under these
conditions [24]. However, the effect of BU on the development of spermatogenesis in immature mice
has not been examined.
As prepubertal males do not produce spermatozoa, the cryopreservation of sperm for fertility
is not an option. However, their testes do contain SSCs, which could be used for future fertility
preservation before aggressive anti-cancer treatments. While germ cell and testicular tissue
transplantation has been shown to generate fertile sperm in rodents and other animal species,
this has not yet been shown in humans [28–33]. In addition, Sato et al. showed that the testicular
organ culture produced fertile sperm in vitro [34]. Recently, our group showed the induction of
mouse spermatogonial cells from immature mice to proliferation and differentiation to meiotic and
postmeiotic stages, including the generation of sperm-like cells in three-dimensional (3D) in-vitro
culture systems, such as in soft-agar culture systems (SACS) [35,36] and methylcellulose culture
systems (MCS) [37]. Using a 3D in-vitro culture system (MCS), we also were able to induce the
proliferation and differentiation of spermatogonial cells isolated from prepubertal monkeys to meiotic
and postmeiotic cells, including the development of round-like spermatid cells [5]. Recently, we were
able to induce human spermatogonial cells from prepubertal cancer patients so as to develop meiotic
and postmeiotic cells that included the generation of sperm-like cells in MCS [38].
Our hypothesis is that the testicular cells from BU-treated immature mice contain biologically
active spermatogonial cells, and these cells could be induced using a 3D in-vitro culture system (MCS)
to proliferate and differentiate to the meiotic and postmeiotic stages that include sperm-like cells.
Furthermore, these cells could be used in the future to develop embryos using intracytoplasmic sperm
injection (ICSI) technology.
2. Results
2.1. Effect of BU on the Testicular Parameters of Immature Mice
Our results show that the treatment of immature mice with BU significantly decreased the
testicular weight (as presented by the ratio of the testicular weight/testicular body) immediately,
one week after BU injection, until eight weeks, as compared with the control (Figure 1A). After two
weeks, a gradual increase in the testicular weight was observed equal to the control after 10 weeks
(Figure 1A). In parallel, the BU injection led to damage in the histology of the seminiferous tubules
(STs) of the testis (presented histology of the seminiferous tubules after six weeks of BU treatment),
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as follows: normal (Figure 1B1), moderate damage (Figure 1B2), and severe damage (Figure 1B3).
The damage effect of the BU on the STs was significantly higher (the percentage of damaged STs)
in parallel to the reduction in the testicular weight, while in the beginning, recovery of the STs was
observed after six weeks to be similar to the control after 10 weeks (Figure 1C).
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Figure 1. Effect of busulfan (BU) on testicular and body weight and on testicular histology: BU was 
intraperitoneally injected (i.p; 45 mg/kg in 100 µL). After 0.5–12 weeks, mice were weighed, and the 
testes were removed and weighed. Part of the testes were fixed in Bouin’s solution (for histological 
evaluation), while the other part was frozen at −70 °C for RNA extraction and/or for the preparation 
of total protein. The ratio of the testes weight/body weight after 0.5–12 weeks of BU injection 
compared to the control (CT) (DMSO) is presented (A). The histology of the seminiferous tubules 
after BU treatment was normal (B1), showed moderate damage (B2), or showed severe damage (B3). 
A summary of the seminiferous tubule damage after 0.5–12 weeks of BU treatment compared to the 
CT is presented (C). ×40 light microscope magnification (100µm scale). ** p < 0.01 and *** p < 0.001  
2.2. Effect of BU on VASA and SALL4 Spermatogonial Cells in Testicular Tissue of Immature Mice 
The testicular tissue from the BU-treated and control mice were prepared for VASA and 
SALL4 by immunohistochemical staining. Here, we present the results of staining from one and 
four weeks (with a severe effect of BU on the histology of the STs), and 12 weeks (with the recovery 
of the STs) after BU treatment (Figure 2A,C, respectively). Our results show a significant reduction 
in the stained cells of VASA and SALL4/seminiferous tubules 0.5–6 weeks after BU injection, as 
compared with the control (Figure 2B,D, respectively). A gradual increase in the number of VASA 
and SALL4 stained cells per seminiferous tubule was detected 2–12 weeks after BU injection, when 
they became similar to the control after eight weeks for VASA and SALL4 (Figure 2B,D, 
respectively). 
In order to examine the effect of the BU treatment of immature mice on the capacity of their 
spermatogonial cells to develop spermatogenesis in vitro, we used immature mice after 10 days of 
BU treatment, the time point when, according to our results, there is a severe effect of BU (Figures 1 
and 2). 
Fig re 1. ffect of b s lfa ( ) o testic lar a bo y eig t a o testic lar istology: as
intraperitoneally injected (i.p; 45 g/kg in 100 µL). fter 0.5–12 eeks, ice ere eighed, and the
testes ere re oved and eighed. Part of the testes ere fixed in Bouin’s solution (for histological
evaluation), while the other part was frozen at−70 ◦C for RNA extraction and/or for the preparation of
total protein. The ratio of the testes weight/body weight after 0.5–12 weeks of BU injection compared to
the control (CT) (DMSO) is presented (A). The histology of the seminiferous tubules after BU treatment
was normal (B1), showed moderate damage (B2), or showed severe damage (B3). A summary of the
seminiferous tubule damage after 0.5–12 weeks of BU treatment compared to the CT is presented (C).
×40 light microscope magnification (100 µm scale). ** p < 0.01 and *** p < 0.001.
2.2. Effect of BU on VASA and SALL4 Spermatogonial Cells in Testicular Tissue of Immature Mice
The testicular tissue from the BU-treated and control mice were prepared for VASA and SALL4
by immunohistochemical staining. Here, we present the results of staining from one and four weeks
(with a severe effect of BU on the histology of the STs), and 12 weeks (with the recovery of the STs)
after BU treatment (Figure 2A,C, respectively). Our results show a significant reduction in the stained
cells of VASA and SALL4/seminiferous tubules 0.5–6 weeks after BU injection, as compared with the
control (Figure 2B,D, respectively). A gradual increase in the number of VASA and SALL4 stained
cells per seminiferous tubule was detected 2–12 weeks after BU injection, when they became similar to
the control after eight weeks for VASA and SALL4 (Figure 2B,D, respectively).











Figure 2. Effect of busulfan (BU) on VASA- and SALL4-positve cells in testicular tissue: BU was
i.p injected, as described in Figure 1. Testicular tissue from different time points (1 week, 4 weeks,
and 12 weeks) after the BU or control (CT) injection were examined for VASA- and SALL4-positive cells
(A and C, respectively) using immunohistochemical staining. Negative control (NC) of the tissue is
presented. Summary of the VASA-positive cell staining/tubule or SALL4-positive cell staining/tubule
at different time points (0.5–12 weeks) after the BU or CT treatments is presented (B and D, respectively).
× 40 light microscope magnification (100 µm scale). $ indicates comparison between control and
treatment. * indicates comparison between weeks of control and first week of control. #—indicates
comparison between weeks of BU-treatment and first week of BU-treatment. $$$, ***, ### p < 0.001,
$$ p < 0.01, # and $ p < 0.05. Black arrows indicate the stained cells.
In order to examine the effect of the BU treatment of immature mice on the capacity of their
spermatogonial cells to develop spermatogenesis in vitro, we used immature mice after 10 days of BU
treatment, the time point when, according to our results, there is a severe effect of BU (Figures 1 and 2).
2.3. Effect of BU on Testicular Cell Count and Proliferation from Immature Mice 10 Days After Injection
Our results show that BU significantly decreased the testicular weight (presented as a ratio of
testicular weight to body weight (p < 0.001) (Figure 3A) and testicular cell count compared with the
control (CT) (p < 0.001) (Figure 3B). In addition, it damaged the seminiferous tubules compared with
the control (Figure 3C), and significantly decreased the seminiferous tubule cell proliferation compared
with the control (PCNA staining as an indicator of cell proliferation) (Figure 3D).






Figure 4 Figure 3. Effect of 10-day post busulfan (BU) treatment on testicular body weight, cell count,
and proliferation: BU or dimethyl sulfoxide (DMSO) (control, CT) were i.p injected, as described
in Figure 1. Ten days after the injection, the testes were weighed (A), the total cells in the seminiferous
tubules were counted (B), the histology of testicular tissue was examined using hematoxylin and
eosin (H&E) staining (C), and cell proliferation in testicular tissues was evaluated using proliferating
cell nuclear antigen (PCNA) staining (D). Negative control (NC) of the tissue is presented. ×40 light
microscope magnification (100 µm scale). *** p < 0.001.
2.4. Effect of BU on Subpopulations of Spermatogenic Cells from Immature Mice 10 Days after Injection
We examined the effect of BU on subpopulations of spermatogonial cells according to cell
membrane markers (by fluorescence-activated cell sorter (FACS) analysis; Figure 4A) and cytoplasmic/
nuclear markers (by immunofluorescence staining; Figure 4B). Our results show that the injection of
BU into immature mice did not affect the number of alpha-6-integrin positive cells, but significantly
increased their percentage compared to the control (p < 0.001), as examined by FACS analysis
(Figure 4C,D, respectively). However, the injection of BU into immature mice significantly decreased
the number and percentage of C-KIT- (p < 0.001), G-CSFR- (p < 0.01), and THY-1-positive cells
(p < 0.001), as examined by FACS analysis (Figure 4C,D, respectively). Using the immunofluorescence
staining (Figure 4B) and qPCR analyses (Figure 5C), we could show that injection of BU to immature
mice significantly decreased the cell number (Figure 5A), the percentages of the stained cells (Figure 5B),
and the expression levels of the VASA and SALL4 cells (premeiotic cells), CREM-1 cells (meiotic cells),
and ACROSIN (meiotic and postmeiotic cells) compared with the control (Figure 5C).
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isolated from the seminiferous tubules. Spermatogonial cells with the membrane markers: alpha-6-
INTEGRIN (alpha-6-INT), c-KIT, G-CSF-R, and THY1 were identified by FACS using specific 
antibodies for each marker (A). Spermatogenic cells were identified by immunofluorescence 
staining for specific markers [premeiotic (CD9, VASA, and SALL4), meiotic (CREM, BOULE, and 
ACROSIN), and postmeiotic (ACROSIN)] (B). The above identified spermatogonial cells were 
counted and calculated per testicle (C), and their percentage was evaluated (D). ** p < 0.01 and *** p 
< 0.001. 
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identified spermatogenic cells were counted and calculated per testicle (A), and their percentage 
was evaluated (B). Their expression was analyzed by qPCR analysis (fold of increase compared to 
control) (C). ×40 light microscope magnification (100 µm scale). ** p < 0.01 and *** p < 0.001 
Figure 4. Effect of 10-day post busulfan (BU) treatment on spermatogonial cell counts and percentages,
as examined by fluorescence-activated cell sorter (FACS) analysis, as follows: BU or DMASO (control,
CT) were i.p injected, as described in Figure 1. Ten days after the injection, the testes were removed,
seminiferous tubules were separated, and the cells were enzymatically isolated from the seminiferous
tubules. Spermatogonial cells with the membrane markers: alpha-6-INTEGRIN (alpha-6-INT),
c-KIT, G-CSF-R, and THY1 were identified by FACS using specific antibodies for each marker (A).
Spermatogenic cells were identified by immunofluorescence staining for specific markers [premeiotic
(CD9, VASA, and SALL4), meiotic (CREM, BOULE, and ACROSIN), and postmeiotic (ACROSIN)] (B).
The above identified spermatogonial cells were counted and calculated per testicle (C), and their
percentage was evaluated (D). ** p < 0.01 and *** p < 0.001.
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Figure 5. Effect of 10-day post busulfan (BU) treatment on spermatogenic cell counts, percentages
and expression: BU or DMASO (control, CT) were i.p injected, as described in Figure 1. Ten days
after the injection, the testes were removed, seminiferous tubules were separated, and cells were
enzymatically isolated from the seminiferous tubules. The premeiotic (CD9, VASA, and SALL4),
meiotic (CREM, BOULE, and ACROSIN), and postmeiotic (ACROSIN) cells were identified by
immunofluorescence staining using the antibodies specific for each marker (Figure 4B). The above
identified spermatogenic cells were counted and calculated per testicle (A), and their percentage
was evaluated (B). Their expression was analyzed by qPCR analysis (fold of increase compared to
control) (C). ×40 light microscope magnification (100 µm scale). ** p < 0.01 and *** p < 0.001.
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2.5. Effect of FSH, TNF, and Testicular Homogenates on the Capacity of Spermatogonial Cells from BU-Treated
Immature Mice to Develop Spermatogenesis In Vitro
The isolated spermatogonial cells from the seminiferous tubules of mice 10 days after BU treatment
were cultured in vitro in methylcellulose (a 3D culture system) containing StemPro, KSR (knock-out
serum replacement), LIF (leukemia inhibitory factor), GDNF, and FGF (fibroblast growth factor)
without (control; CT) or with addition of follicle stimulating hormone (FSH) (7.5 IU/mL), TNF
(20 pg/mL), or homogenates (60 µg/mL) from two-week-old GFP mice or six-week-old GFP mice
for four weeks (see Materials and Methods section). Our results show that spermatogonial cells from
BU-treated mice could proliferate (formation of clusters/colonies) in vitro (Figure 6A) and differentiate
to meiotic and postmeiotic stages (generate CREM-1 and ACROSIN cells) under control conditions
(CT), compared with before the culture (Figure 6B,D). The addition of FSH to the cultures showed a
significant increase in the percentages of the CD9, CREM-1, and BOULE cells compared with the control
(CT) (p < 0.0.5, p < 0.05, and p < 0.001, respectively), but did not affect the ACROSINE cell development
(Figure 6B). The addition of TNF-α to the cultures significantly increased the percentages of the
CD9, CREM-1, BOULE, and ACROSIN cells in the culture, compared with the control (CT) (p < 0.0.5,
p < 0.01, p < 0.05, and p < 0.05, respectively) (Figure 6B). In addition, the addition of homogenates
from two-week-old (young homogenates) mice did not significantly affect the percentages of the
developed spermatogenic cells in the culture compared to the control (CT) (Figure 6C). However,
the addition of homogenates from six-week-old (adult homogenates) mice to the cultures did not
affect the percentages of the CD9, VASA, BOULE, and CREM cells, but significantly increased the
percentages of the ACROSINE cells in the culture compared with the control (CT) (p < 0.001) (Figure 6D).
In addition, the homogenates from adult mice induced the development of spermatogonial cells from
BU-treated mice to generate sperm-like cells with complete morphology (head, neck, and tail) in vitro,
as examined by immunofluorescence staining (Figure 6E) and PAS (Figure 6F). Some sperm samples
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Figure 6. Development of spermatogenesis in vitro from BU-treated immature mice: Ten days after
BU injection (see Figure 1), the testes were removed, seminiferous tubules were separated, and cells
were enzymatically isolated and cultured in a methylcellulose culture system (MCS). The MCS was
composed of 42% methylcellulose, KSR (10%), StemPro, and growth factors (GDNF (glial cell line
derived nerve growth factor), LIF (leukemia inhibitory factor), FGF (fibroblast growth factor), and EGF
(epidermal growth factor)) (see Methodology). In some wells, we also added TNF-α (20 pg/mL), FSH
(7.5 IU/mL), or testicular homogenates from immature mice (60 µg/mL) or testicular homogenates
from GFP-adult mice (60 µg/mL). Every 10–14 days, we added new media containing the same
composition of factors that was added in the beginning of the culture. After 4–6 weeks, the developed
colonies and cells (A) were collected, and the cells were fixed using cold methanol and were stained
using immunofluorescence staining, using specific antibodies for markers of the premeiotic (CD9 and
VASA), meiotic (CREM, BOULE, and ACROSIN), and postmeiotic (ACROSIN) cells. The effect of FSH
and TNF-alpha (B) testicular homogenates from immature (C) or adult (D) mice on the development
of spermatogenic cells in vitro compared to before the culture or the control (CT; after culture in the
presence of growth factors) were examined. In addition, the development of the sperm-like cells in the
cultures was examined according to the DAPI staining of sperm head morphology [E; E1—positive
control of a sperm head (H); E2—a single sperm head developed in the culture; E3—a group of sperm
heads developed in the culture] or periodic acid–Schiff (PAS) staining [F; F1—a group of sperm-like
cells with heads (H) and tails; F2—a few sperm-like cells with complete morphology of head (H),
neck (N), and tails (T)]. ×40 light microscope magnification (100 µm scale). * p < 0.05, ** p < 0.01 and
*** p < 0.001.
3. Discussion
Our results show, for the first time, the presence of biologically active spermatogonial cells in the
testes of immature mice treated with busulfan. These cells were able to proliferate and differentiate to
meiotic and postmeiotic cells, and to develop sperm-like cells in vitro, using methylcellulose as a 3D
in-vitro culture system.
The treatment of immature mice with BU significantly reduced their testicular weight for a period
of eight weeks after the BU injection. This was in parallel with an increase in the percentage of the
damaged seminiferous tubules. In addition, a significant reduction in the number of SALL4 and
VASA cells/seminiferous tubules was observed during this period. The restoration of the testicular
tissue weight began after two weeks, and was retained similar to that of the control after 10 weeks.
This was in parallel to an increase in the number of SALL4 and VASA cells/seminiferous tubules and
other developing spermatogenic cells (see histological sections). An increase in the number of normal
seminiferous tubules was detected four weeks after BU injection. It is possible that the significant
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reduction in testicular weight could be related to the severe damage of the seminiferous tubules,
and that restoration of these tubules increased the testicular weight. Thus, it is possible that even
though the BU treatment of the immature mice led to severe damage of most of the seminiferous tubules
and a reduction in their spermatogonial cell counts/seminiferous tubules, the survivor spermatogonial
cells and somatic cells were still biologically active and capable of restoring the germinal epithelium
of the seminiferous tubules. These results may suggest that, under some chemotherapy treatment
conditions, when biologically active spermatogonial cells and somatic cells remain, it is possible
that spermatogenesis may be restored. Our results show that the BU treatment of immature mice
significantly decreased the different subpopulations of spermatogonial cells (α-6-INTEGRIN, c-KIT,
G-CSF-R, THY-1, CD9, VASA, and SALL4 positive cells) 10 days after the injection. In addition,
the cells that stained/expressed CREM-1 and BOULE (meiotic cells) and expressed protamine (RNA
expression) were examined in the seminiferous tubules of the BU-treated immature mice, and were
significantly lower compared to the control. However, the acrosin stained cells were not present,
but their expression was significantly lower following BU treatment. Therefore, it is possible to suggest
that after 10 days of BU treatment, some spermatocytes are still present and/or the spermatogonia
has already started to differentiate in the seminiferous tubules to generate spermatocytes. It was
demonstrated that spermatocytes express protamine RNA, but the process of its translation to protein
is under suppression. Therefore, we suggest that, in our system, the spermatocytes are the source of
the protamine RNA expression and not the elongated spermatids.
Thus, the effect of the BU treatment may lead to an imbalance in the factors produced by testicular
somatic cells that are involved in the regulation of spermatogenesis, which leads to changes in
the SSCs microenvironment and, as a result, may lead to impairment in the development process
of spermatogenesis.
Because after BU treatment of immature mice, some biologically active spermatogonial cells
survive the treatment, we used these cells (after 10 days of BU treatment) for the possible
development of spermatogenesis in vitro in 3D in-vitro culture conditions. Our results show that
these spermatogonial cells were able to proliferate (form colonies) after four weeks of culture in the
presence of different growth factors (LIF, GDNF, FGF, and EGF) and denovo Sertoli cells. The addition
of these factors that present in the testicles under physiological conditions, such as FSH or TNF-α,
to MCS, significantly increased the proliferation of the spermatogonial cells and their differentiation
to meiotic and postmeiotic cells, compared with the control (CT; without those factors). However,
we could not identify the development of sperm-like cells under these conditions. As testicular
tissue from adults contains various factors (endocrine and paracrine/autocrine factors) that together
induce the development of complete spermatogenesis in vivo, we decided to add homogenates
from sexually immature and adult mice (the composition of factors is different, and the stages of
spermatogenesis are also different at these ages) to our in-vitro MCS. Our results show that the addition
of testicular homogenates from adult mice significantly increased the capacity of spermatogonial cells
from BU-treated immature mice (after 10 days of BU injection) to develop meiotic and postmeiotic
cells compared to the control (CT; without addition of homogenates) in MCS. Under these conditions,
we also were able to identify the development of sperm-like cells (appearance of sperm-like heads,
as identified by DAPI, using IF staining) and sperm-like cells with complete morphology (head, neck,
tail), as examined by PAS staining. Some of these cells were identified as individuals, while others were
identified in clusters. These results may suggest the presence of biologically active spermatogonial
cells in the testicular tissue of immature mice treated with BU. These spermatogonial cells were able to
develop complete spermatogenesis, including the generation of sperm-like cells in MCS-contained
testicular homogenates from adult mice. These results may suggest that these homogenates contain a
combination of growth/differentiation and possibly endocrine factors, that together (in the suitable
balance and ratio) were able to provide conditions in vitro similar to in-vivo conditions and, thus,
to induce the development of complete spermatogenesis in vitro. The testicular homogenates were
prepared from GFP mice, were frozen and thawed several times, and filtered before addition to the
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culture. This was performed to exclude the possibility that the identified sperm developed in MCS
may be from the homogenates and not from the developed spermatogonial cells (the developed sperm
was colorless, rather than green). On the other hand, the addition of homogenates from immature
mice to spermatogonial cells from BU-treated mice did not affect the number of premeiotic, meiotic,
and postmeiotic cells developed in MCS compared with the control (CT). These homogenates did not
contain the factors present in the testes of adult mice and, therefore, could not induce the development
of spermatogenesis similar to in-vivo conditions.
Thus, this is the first study that shows the presence of bioactive spermatogonial cells in the
BU-treated immature mice with the capacity to develop complete spermatogenesis, including the
generation of sperm-like cells under in-vitro culture conditions. These results are in harmony
with our recent study that showed the presence of biologically active spermatogonial cells in the
testes of chemotherapy-treated prepubertal boys with cancer. These cells were developed to meiotic
and postmeiotic cells, including the generation of sperm-like cells in MCS [38]. Using 3D culture
systems (MCS and/or SACS), we were able to induce the development of spermatogonial cells from
normal immature mice (seven days old) to meiotic and postmeiotic cells, including the generation
of sperm-like cells [35–37]. In addition, we were able to induce the development of spermatogonial
cells from prepubertal monkeys to meiotic and postmeiotic cells in MCS [5]. In conclusion, our results
suggest that MCS is a possible 3D system to induce the development of spermatogonial cells to
meiotic and postmeiotic stages, including the generation of sperm-like cells. This system still needs
optimization to increase the number of the developed cells (including sperm-like cells) and its efficiency.
In addition, there is a need to evaluate the functionality of the developed sperm-like cells and their
DNA quality, and its epigenetics. Therefore, in our institution, we encourage prepubertal aggressive
chemotherapy/radiotherapy-treated patients without the capacity to generate sperm to cryopreserve
testicular tissue. Our previous study has further encouraged us and other to continue this kind of
recommendation for prepubertal patients and their families.
4. Materials and Methods
4.1. Animals
This study was performed in accordance with the Guiding Principles for the Care and Use of
Research Animals Promulgated by the Society for the Study of Reproduction. It was confirmed by
the Ben-Gurion University Ethics Committee for Animal Use in Research (IL-17-11-2014). Sexually
immature seven-day-old ICR (CD-1) (Institute of Cancer Research) male mice (Envigo Laboratories,
Jerusalem, Israel) were used.
4.2. Busulfan Treatment
Seven-day-old immature male mice were intraperitoneally (i. p) injected with a single dose
of busulfan (45 mg/kg; 100 µL/mouse) (BU), which was dissolved with DMSO (1:1 with distilled
water). Control mice were injected (i.p) with DMSO alone (1:1 with distilled water). The mice were
sacrificed after 3 days–12 weeks of injection in one-week intervals. The body and testes were weighed.
The testes were fixed in Bouins’ solution for histological evaluation and/or frozen in−70 ◦C for protein
examination and/or RNA extraction, or were immediately used for tubular cell isolation (after 10 days
of BU injection).
4.3. Preparation of Testicular Homogenates
The tunica albuginea were removed. Then, the testes were stored in a protease inhibitor solution
(1:250; Sigma, St. Louis, MN, USA) at −20 ◦C. Thereafter, the tissues were homogenized (with the
tissues in ice). The homogenates were centrifuged (13,000 rpm for 15 min at 4 ◦C), and the upper phase
was collected and filtered through a 0.45 µm filter (Merck KGaA, Darmstadt, Germany) and stored at
−80 ◦C.
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4.4. Isolation of Tubular/Spermatogonial Cells
The tubular cells were isolated from the testes of the BU-treated mice (10 days after BU injection).
The testicular cell suspensions were obtained as described by Abu Elhija et al. [35]. Briefly, the testes
were decapsulated and mechanically digested by multiple aspirations through pipette tips and a
50-mL syringe containing 20-mL phosphate-buffered saline (PBS). The tubules, which were settled by
gravity, were subjected to enzymatic digestion (collagenase type V and DNAse). The suspension of
the single cells was filtered through a sterile cell strainer (70 µM; BD Biosciences) and washed with
5 mL MEM (minimum essential media) (centrifugation at 100× g for 5 min). After centrifugation,
the media were removed and the pellet of the cells in the bottom of the tube was suspended in 1 mL of
fresh StemPro-34. The cells were suspended in StemPro-34 and were counted under phase-contrast
microscopy in a Neubauer counting chamber.
4.5. Culture of Isolated Spermatogonial Cells in Methylcellulose Culture System (MCS)
The isolated tubular cells were cultured (2 × 105 cells/well/500 µL) in methylcellulose (R&D
systems, Minneapolis, MN, USA) (42%) as a three-dimensional (3D) culture system, and 58% of the
media were composed of 33% StemPro-34 medium; 10% KSR (knock-out serum replacement) (Gibco,
USA); and different growth factors such as human rEGF (recombinant epidermal growth factor)
(20 ng/mL) (Biolegend, San Diego, CA, USA), human rGDNF (glial cell line derived nerve growth
factor) (10 ng/mL) (Biolegend), human rLIF (leukemia inhibitory factor) (10 ng/mL) (Biolegend),
and human r-bFGF (basic fibroblast growth factor) (10 ng/mL) (Biolegend) [38]. The cells were
incubated for four weeks in a CO2 incubator at 37 ◦C. Every 7–10 days, we added 50 µL/well of
fresh concentrated (× 10) enriched StemPro-34 medium (containing all the growth factors used in the
primary culture) to the cell cultures. We tried to match the physiological timing of the development of
the cell growth in the culture as closely as possible to that of the mouse spermatogenesis (around five
weeks). At the end of the incubation period in MCS, we added 0.5 mL of PBS to the culture wells that
contained 0.5 mL MC, mixed by pipetting, and collected the suspension in 15-mL tubes. The tubes
were centrifuged at 1600 RPM for 10 min. We removed most of the volume and collected the remainder
of around 100 µL from the bottom of the tubes. This volume, which contained the cells, was smeared
on a slide for histological examination and/or collected and kept at −70 ◦C in a lysis solution to be
used for RNA extraction.
4.6. Testicular Tissues Immunostaining
This was performed as described previously [5,35,38]. Briefly, the testicular tissues were fixed
in Bouin’s solution (Kaltek, Italy) and were paraffin-embedded. Sections of 5 µm were placed on
superfrost plus slides (Thermo, Braunschweig, Germany) for histological evaluation and for the
immunofluorescence staining of SALL4, VASA, and PCNA. The deparaffinated section slides were
treated with xylene and ethanol (BIO-LAB, Jerusalem, Israel) for 20 min. After washing with a
phosphate buffer solution (PBS) (Biological Industries, Beit HaEemek, Israel), the antigen retrieval
of the sections was performed in heated 36% urea solution (Millpore) at in a warm microwave for
5 min (twice). After washing, the nonspecific adhesion sites in the tissues and cells were blocked using
a 5% donkey serum (Biological Industries) for 30 min at room temperature. Following the removal
of the blocking buffer, the first antibodies were added, as follows: polyclonal rabbit anti-human
VASA (Santa Cruz, CA, USA; 1:1000), polyclonal rabbit anti-mouse SALL4 (Abcam, Cambridge, UK;
1:400), and PCNA (Santa Cruz, CA, USA; 1:200). After overnight incubation at 40 ◦C, the slides were
washed, and the specific secondary antibodies were added compatibly to the first antibodies (donkey
anti-rabbit IgG (Cy3), donkey anti-goat IgG (Cy3), goat anti-mouse IgG (Rhodamine red); Jackson
Immuno Research (West Grove, PA, USA) for 40 min at room temperature. After washing, the slides
were dried and DAPI, which stains the nuclei blue, was added to the tissues, and the cover slides
were applied. The negative control was incubated in a blocking buffer instead of the first antibody.
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The specificity of the staining was also examined in the testicular tissue using the relevant IgG isotype
as the negative control. The slides were examined for staining using a fluorescence microscope (Nikon
Eclipse 50 I; Tokyo, Japan).
4.7. Immunostaining of Testicular Cells
The cell immunostaining was performed according to our previous studies [5,35,38]. Briefly,
the isolated cells from the mouse seminiferous tubules or those that were collected from the
in-vitro culture (MCS) were fixed in cold methanol for 20 min. The process was performed for
the immunostaining of testicular tissue, as mentioned above, after antigen retrieval. Following
the removal of the blocking buffer, the first antibodies were added, as follows: polyclonal rabbit
anti-mouse SALL4 (Abcam, Cambridge, UK; 1:400), polyclonal rabbit anti-mouse VASA (Santa Cruz;
1:100), polyclonal rabbit anti-mouse CD9 (Santa Cruz, CA, USA; 1:100), polyclonal rabbit anti-mouse
BOULE (Santa Cruz; 1:50), polyclonal rabbit anti-mouse CREM-1 (Santa Cruz; 1:50), and polyclonal
rabbit anti-mouse ACROSIN (Santa Cruz; 1:200). Following overnight incubation at 4 ◦C, the slides
were washed and treated as described for testicular tissue immunostaining.
4.8. Hematoxylin Eosin Staining
The cut tissue on the slides was deparaffinized in a K-clear solution 2× for 4 min, and rehydrated
in an ethanol concentration 2× ethanol 100% for 2 min each, then 1× ethanol 70% for 2 min and
1 × ethanol 50% for 2 min, and then in deionized water for 2 min. The slides were incubated in a
hematoxylin reagent for 1 min, then rinsed in deionized water three times and rinsed in tap water for
5 min to allow for the stain to develop. Next, the slides were dipped in an eosin solution, then in DDW
(double distilled water) until the eosin did not stain the water. This was followed by dehydration
by rinsing the slides in ascending ethanol concentrations, as follows: 1 × 50% ethanol for 2 min,
1 × 70% ethanol for 2 min, 2 × 100% ethanol for 2 min each, and then rinsed 2 × in K-clear 2 min each.
The slides were dried and coverslips using permount were applied.
The slides were rinsed in DDW 2× for 5 min each. Then, 200 µL of periodic acid reagent was
added to fully cover the slides, and they were incubated for 10 min. The slides were washed in tap
water for 3 min, and the cells were dipped twice in DDW. Then, 200 µl of Schiff’s reagent was added,
followed by incubation for 15 min. The slides were washed in running tap water for 10 min, rinsed in
DDW for 5 min, and stained in hematoxylin for 1 min. The color was developed in running tap water
for 5 min, and dehydrated by rinsing the slides in ascending ethanol concentrations, as follos: 1 × 50%
ethanol for 2 min, 1 × 70% ethanol for 2 min, 2 × 100% ethanol for 2 min each, then rinsed 2 × in
K-clear 2 min each. The slides were dried and coverslip were applied using permount.
4.9. Flow Cytometry Analysis
The isolated cells were suspended in 2 mL ice-cold PBS containing 2% BSA and 1 mM EDTA,
and incubated with 0.5–1µg of anti-mouse CD16/CD32 purified per 100 µL for 10–20 min at 4 ◦C before
staining. Then, the cells were incubated with the live/dead dye for 20 min. The cells were washed once
in PBS, and stained with anti-THY-1.2 antibody conjugated to Alexa fluor 488, anti-α-6-INTEGRIN
antibody conjugated to PE (Phycoerythrin), anti-c-KIT antibody conjugated to APC (Allophycocyanin),
and anti-GCSFR antibody conjugated to PercP/cy5.5 at 4 ◦C for 45 min. Cells were washed once in
PBS, resuspended at a concentration of 1–2 ×106 cells/mL, and analyzed on a BD FACS vantage cell
sorter. The cells that did not receive primary antibodies were used to gate the positive staining cell
population. Live/dead dye was used to gate out the dead cells.
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4.10. Gene Expression–PCR amplification
4.10.1. Real-Time Quantitative PCR
Isolated cells: Enzymatically isolated testicular cells and developed cells from in-vitro cultures
were mixed with 250 µL of lysis buffer and 2-mercaptoethanol mixture (GenElute Total RNA
Miniprep Kit; Sigma, St. Louis, USA). The lysates were frozen at −80 ◦C for later RNA extraction.
The cDNA synthesis was performed according to the qScript cDNA Synthesis Kit (Quantabio,
Beverly, MA 01915, USA), using random hexamers, and qPCR was performed using specific
primers for each examined spermatogenesis marker: gfr-α (forward:CAGTTTTCGTCTGCTGAGGTTG;
reverse: TTCTGCTCAAAGTGGCTCCAT; product size, 141 bp), VASA (forward: AGTATTCATGGT
GATCGGGAGCAG; reverse: GCAACAAGAACTGGGCACTTTCCA; product size, 83 bp), CREM-1
(forward:TTCTTTCACGAAGACCCTCA; reverse: TGTTAGGTGGTGTCCCTTCT; product size,
138 bp), BOULE (forward: AACCCAACAAGTGGCCCAAGATAC; reverse: CTTTGGACACTCCA
GCTCTGTCAT; product size, 163 bp), protamine (forward: TCCATCAAAACTCCTGCGTGA;
reverse: AGGTGGCATTGTTCCTTAGCA; product size, 114 bp), ACROSIN (forward: TGTCCGTGGT
TGCCAAGGATAACA; reverse: AATCCGGGTACCTGCTTGTGAGTT; product size, 149 bp), and the
calibrator gene GAPDH (forward: ACCACAGTCCATGCCATCAC; reverse: CACCACCCTGTTGCT
GTAGCC; product size, 450 bp). The qPCR reaction was performed following the 2 × qPCRBIO
SyGreen Blue Mix Hi-ROX (PCR Biosystems Ltd., Aztec House, 397–405 Archway Road, London,
UK) protocol and was performed using the LightCycler 96 real-time PCR machine (Roche,
Roche Diagnostics Corporation, Roche CustomBiotech, Indianapolis, IN, USA). According to the
manufacturer introductions for the SYBR Green dye, we ran a PCR profile including a three-step
amplification program and subsequent melting, described as follows: preincubation 10 min at 95 ◦C,
40 cycles of 15 s at 95 ◦C, 15 s at 60 ◦C (all the primers were designed with this specific annealing
temperature), and 10 s at 72 ◦C. Melting cycle: 10 s at 95 ◦C, 60 s at 65 ◦C, and 1 s at 97 ◦C. The PCR
products were identified and distinguished using the generated melting curve. The “threshold cycle”
(Ct) values, representing the cycle number at which the sample fluorescence rises statistically above
the background and crossing points (CP) for each transcript were defined. The relative quantity of
the gene expression was analyzed using the 2−∆∆Ct method. The results were expressed as the fold of
increase related to the GAPDH of the same examined sample.
The microscopy samples were observed with an Olympus IX70 microscope (Olympus, Novato,
CA, USA). The digital images and signal intensity charts were prepared using Image-Pro Plus (Media
Cybernetics, Bethesda, MD, USA), Microsoft Excel, and Adobe Photoshop 7.0 software.
4.10.2. Data Analysis and Statistical Evaluation
Each culture condition was tested in 4–6 wells. The plotted data are means calculated from
3–10 repeats of the experiment. The standard deviation represents the variability between the
independent experiments.
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